Rather than relying on reported cases, monitoring populations through blood testing is important for understanding how it spreads and for guiding targeted vaccination.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
WHO experts are seeing the same chikungunya warning signs that occurred two decades ago, when the virus swept across Indian Ocean countries.
The cases were reported in northern Mozambique near the Tanzanian border.
Despite declines in 2 high-burden countries, cases are rising in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea.
Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake in affected populations.
Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social behaviors.
Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or breastfeeding women.
Though the surge in Sierra Leone has received much of the attention, cases are also rising in two other countries in West Africa: Ghana and Liberia.
Twenty five countries have reported outbreaks, including newly affected Sierra Leone where infections are surging.
Scientists estimate a precurser to the 2022 strain first emerged in Nigeria in August 2014 and spread to 11 Nigerian states before human infections were detected in 2017.
Population density and tourism are among factors driving infections in Sierra Leone, which made up 53% of mpox illnesses in Africa last week.
